iBio, Inc. Common Stock (NASDAQ:IBIO) — Market Cap & Net Worth
Market Cap & Net Worth: iBio, Inc. Common Stock (IBIO)
iBio, Inc. Common Stock (NASDAQ:IBIO) has a market capitalization of $57.83 Million ($57.83 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21424 globally and #4731 in its home market, demonstrating a -5.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying iBio, Inc. Common Stock's stock price $1.60 by its total outstanding shares 36143561 (36.14 Million). Review iBio, Inc. Common Stock total liabilities to assess the company's total debt and financial obligations.
iBio, Inc. Common Stock Market Cap History: 2025 to 2026
iBio, Inc. Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $69.76 Million to $57.83 Million (0.00% CAGR).
iBio, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how iBio, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
174.39x
iBio, Inc. Common Stock's market cap is 174.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $69.76 Million | $400.00K | -$18.38 Million | 174.39x | N/A |
Competitor Companies of IBIO by Market Capitalization
Companies near iBio, Inc. Common Stock in the global market cap rankings as of June 19, 2026.
Key companies related to iBio, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
iBio, Inc. Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, iBio, Inc. Common Stock's market cap moved from $69.76 Million to $ 57.83 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $57.83 Million | -17.10% |
| 2025 | $69.76 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of iBio, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $57.83 Million USD |
| MoneyControl | $57.83 Million USD |
| MarketWatch | $57.83 Million USD |
| marketcap.company | $57.83 Million USD |
| Reuters | $57.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more